Optimising Rare Disease Drug Development

Orphan Drug Designation and Accelerated Regulatory Pathways

Regulatory incentives such as Orphan Drug Designation (ODD) and expedited approval pathways provide critical mechanisms to mitigate development risk and accelerate patient access when applied strategically. Beyond ODD, a range of global programs further support rare disease innovation, including priority review and accelerated approval frameworks, conditional marketing authorisations, adaptive licensing models, protocol assistance and scientific advice programs, fee reductions or waivers, tax credits, market exclusivity extensions, and early access or compassionate use schemes.

Jurisdictions such as the United States, European Union, Japan, and emerging regulatory regions in Asia–Pacific and Latin America have increasingly aligned around flexible evidentiary standards, real-world data integration, and collaborative regulatory review initiatives. Leveraging these complementary incentives in a coordinated global development strategy can meaningfully reduce timelines, de-risk investment, and expand equitable access for patients living with rare diseases.

Aixial Group partners with Sponsors to translate these regulatory tools into execution-ready development programs, aligning designation strategy, evidence generation, and CMC (Chemistry, Manufacturing and Controls) readiness to support efficient, regulator-credible pathways to approval.

Disease Understanding	Designations	Expedited Pathways	CMC & Approval
Natural history	US / EU ODD	FT / BT / AA / PR / RMAT	Comparability
Biomarkers	Significant benefit planning	PRIME / CMA / ILAP	Bayesian designs
Endpoint strategy		Evidence Engine	RWE integration
		Comparability PPQ	Post-approval commitments

Rare Disease and Orphan Drug Foundations

Over 7,000 rare diseases are recognised globally, collectively affecting approximately 350 million people. In the United States, a rare disease affects fewer than 200,000 individuals, while in the European Union it is defined as affecting no more than 1 in 2,000 people. Despite small individual populations, these conditions represent a significant public health burden.

Orphan Drug Designation provides financial, regulatory, and strategic incentives including market exclusivity, fee reductions, and enhanced regulatory engagement. Importantly, orphan designation must be maintained throughout development, particularly in the EU where reassessment at marketing authorisation focuses on prevalence and significant benefit. Aixial supports Sponsors in embedding orphan strategy early to avoid late-stage regulatory risk.

Accelerated Pathways and Evidence Design

Global regulators offer multiple expedited mechanisms to accelerate development and review timelines. In the United States these include Fast Track, Breakthrough Therapy, Accelerated Approval, Priority Review, and RMAT for cell and gene therapies. In Europe, PRIME, Accelerated Assessment, and Conditional Marketing Authorisation provide early access options, complemented by the UK ILAP and Japan’s SAKIGAKE pathway.

Rare disease programs require fit-for-purpose evidence strategies such as natural history studies, externally controlled trials, Bayesian designs, and biomarker-driven endpoints. Aixial integrates regulatory, clinical, and statistical expertise to ensure these approaches meet global regulatory expectations while maximising information from small populations.

	US	EU	UK	Japan
Orphan designation criteria	<200,000 persons	<5 in 10,000 persons	EU UK	<50,000 persons
Market exclusivity duration	7 years	10 years	10 years	10 years
Accelerated review mechanisms	FT / BT / AA AAss	PRIME / AAss	ILAP	/
Conditional approval options	CMA PSP	PIP PIP	CMA PREA	PREA (exempt extension) PREA (exempt extension)

CMC Readiness and Paediatric Strategy

Expedited pathways do not relax CMC requirements. Manufacturing readiness, comparability, stability, and Process Performance Qualification (PPQ) planning must be aligned with accelerated clinical timelines to avoid approval delays. Aixial supports front-loaded CMC strategies to ensure clinical success translates into regulatory approval.

Paediatric planning is both a regulatory requirement and a value driver. In the EU, a compliant Paediatric Investigation Plan (PIP) can extend orphan exclusivity, while in the US orphan indications are exempt from PREA until non-orphan use. Aixial helps Sponsors balance early deferral with long-term lifecycle strategy.

Key Benefits of Orphan Drug Designation

Benefit	Advantage to Sponsors	How a CRO Can Help
Market Exclusivity	Protection from direct competition for several years, allowing sponsors to recoup development costs and secure ROI	Strategic trial design and submission timing to maximize exclusivity and accelerate time to market
Lower Regulatory Fees	Reduced or waived application and review fees, lowering the financial burden of development	Submission management, compliance, and fee reduction guidance
Financial Incentives	Tax credits, grants, and funding programs to offset development costs	Expense tracking and advice on qualifying for incentives
Closer Regulatory Support	Frequent interactions with regulators and early guidance to improve approval chances	Regulatory consultations and agency meeting preparation